group IIF sPLA2 Activators
Group IIF sPLA2 activators are a class of compounds that can indirectly enhance the activity of group IIF sPLA2 by targeting other enzymes and pathways within the phospholipid metabolism network. These compounds work by modulating the activity of other phospholipases or altering the balance of lipid mediators, which in turn affects the substrate availability and functional regulation of group IIF sPLA2. ForIt seems that there was a technical issue with the completion of the response. Let me provide the detailed description of the Group IIF sPLA2 Activators as requested.
Group IIF sPLA2 activators encompass a range of compounds that indirectly enhance the enzymatic activity of Group IIF secretory phospholipase A2. These compounds primarily exert their effects by inhibiting other phospholipase A2 isoforms or modifying signaling pathways that influence lipid metabolism. For example, inhibitors like Indoxam and Methyl arachidonyl fluorophosphonate (MAFP) target cytosolic phospholipase A2 (cPLA2) and calcium-independent phospholipase A2 (iPLA2), respectively. The inhibition of these PLA2 isoforms can lead to a compensatory increase in Group IIF sPLA2 activity due to the reduced competition for phospholipid substrates. Consequently, this redirection of substrate flow can enhance the functional activity of Group IIF sPLA2, as it becomes the primary enzyme to catalyze the hydrolysis of membrane phospholipids into arachidonic acid and lysophospholipids.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MAFP | 188404-10-6 | sc-203440 | 5 mg | $219.00 | 4 | |
MAFP is an irreversible inhibitor of cPLA2 and iPLA2. The inhibition of these PLA2 isoforms can lead to increased substrate availability for group IIF sPLA2, thereby potentially enhancing its activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
MJ33 is a selective inhibitor of calcium-independent phospholipase A2 (iPLA2). Inhibition of iPLA2 can shift cellular phospholipid metabolism towards group IIF sPLA2, potentially increasing its activity due to less competition for substrates. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 can upregulate PLA2 activity indirectly through its signaling pathways. By binding to its receptors, it can activate downstream signaling that enhances the availability of substrates for group IIF sPLA2, thereby potentially increasing its activity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone is a PPARγ agonist that can lead to altered expression and activity of various PLA2s. It can enhance group IIF sPLA2 activity indirectly by modulating the expression of other PLA2 isoforms and affecting overall phospholipid metabolism. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
Wy-14643 is a PPARα agonist that can modify the expression of lipid metabolism-related enzymes, including PLA2s. It can indirectly increase the activity of group IIF sPLA2 by influencing the balance of activity among different PLA2 isoforms. | ||||||
Manoalide | 75088-80-1 | sc-200733 | 1 mg | $269.00 | 9 | |
Manoalide is an inhibitor of sPLA2. It can enhance group IIF sPLA2 activity by selectively inhibiting other sPLA2 isoforms, thus reducing their competition for substrates and indirectly increasing the availability for group IIF sPLA2. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is a serine protease inhibitor that can indirectly enhance group IIF sPLA2 activity by inhibiting proteolytic degradation of sPLA2, leading to a higher functional concentration of the enzyme. | ||||||